Company profile
Microbix Biosystems Inc.
OTC: MBXBF · Healthcare · Biotechnology
Canadian filerHQ Mississauga, ONReports USD
#596 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
60CFH 69DQ —GM 38SS 47
v0.1 · 45/100 weight · provisional
↑ return on assets, balance-sheet leverage · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$11.1M
Rev growth YoY (TTM)
-26.4%
Net income (FY)
-$1.6M
Employees
100
as of 2026-08-20
Market cap
$29.8M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.3M18.6M CAD2025
Net income-$1.6M-2.2M CAD2025
Operating income-$1.1M-1.6M CAD2025
Total assets$26.9M37.5M CAD2025
Liabilities$6.9M9.6M CAD2025
Equity$20.0M27.8M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Microbix Biosystems Inc.’s revenue?
Microbix Biosystems Inc. booked $13.3M in FY2025 revenue, contracting 29% year over year — slower than 75% of Healthcare companies we track, at a -12.1% net margin.
Peers · Healthcare
CV Sciences, Inc.56CHyperfine, Inc.44DCapsoVision, Inc.37DNovo Integrated Sciences, Inc.——Mednow Inc.——Tonix Pharmaceuticals Holding Corp.45DKey facts
CEOCameron L. Groome
SectorHealthcare
IndustryBiotechnology
HeadquartersMississauga, ON
ExchangeOTC: MBXBF
Employees100
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.